dc.contributor.author | Jain, R. K. | en |
dc.contributor.author | Stylianopoulos, T. | en |
dc.creator | Jain, R. K. | en |
dc.creator | Stylianopoulos, T. | en |
dc.date.accessioned | 2019-05-06T12:23:45Z | |
dc.date.available | 2019-05-06T12:23:45Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/48437 | |
dc.description.abstract | Recent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. While the enhanced permeability and retention effect has served as a key rationale for using nanoparticles to treat solid tumors, it does not enable uniform delivery of these particles to all regions of tumors in sufficient quantities. This heterogeneous distribution of therapeutics is a result of physiological barriers presented by the abnormal tumor vasculature and interstitial matrix. These barriers are likely to be responsible for the modest survival benefit offered by many FDA-approved nanotherapeutics and must be overcome for the promise of nanomedicine in patients to be realized. Here, we review these barriers to the delivery of cancer therapeutics and summarize strategies that have been developed to overcome these barriers. Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors. © 2010 Macmillan Publishers Limited. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Nature Reviews Clinical Oncology | en |
dc.subject | bleomycin | en |
dc.subject | daunorubicin | en |
dc.subject | doxorubicin | en |
dc.subject | human | en |
dc.subject | Neoplasms | en |
dc.subject | vincristine | en |
dc.subject | Humans | en |
dc.subject | breast cancer | en |
dc.subject | ovary cancer | en |
dc.subject | paclitaxel | en |
dc.subject | priority journal | en |
dc.subject | clinical trial | en |
dc.subject | drug efficacy | en |
dc.subject | topotecan | en |
dc.subject | review | en |
dc.subject | overall survival | en |
dc.subject | Kaposi sarcoma | en |
dc.subject | solid tumor | en |
dc.subject | unclassified drug | en |
dc.subject | nonhuman | en |
dc.subject | tumor vascularization | en |
dc.subject | drug approval | en |
dc.subject | cancer morphology | en |
dc.subject | drug formulation | en |
dc.subject | drug delivery system | en |
dc.subject | Drug Delivery Systems | en |
dc.subject | particle size | en |
dc.subject | extracellular matrix | en |
dc.subject | Biological Transport | en |
dc.subject | antiangiogenic therapy | en |
dc.subject | nanomedicine | en |
dc.subject | blood vessel permeability | en |
dc.subject | Nanoparticles | en |
dc.subject | blood flow velocity | en |
dc.subject | drug design | en |
dc.subject | drug dosage form comparison | en |
dc.subject | drug penetration | en |
dc.subject | drug transport | en |
dc.subject | endocytosis | en |
dc.subject | genexol pm | en |
dc.subject | Ligands | en |
dc.subject | lymphatic drainage | en |
dc.subject | Lymphatic System | en |
dc.subject | nanotechnology | en |
dc.title | Delivering nanomedicine to solid tumors | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1038/nrclinonc.2010.139 | |
dc.description.volume | 7 | |
dc.description.startingpage | 653 | |
dc.description.endingpage | 664 | |
dc.author.faculty | Πολυτεχνική Σχολή / Faculty of Engineering | |
dc.author.department | Τμήμα Μηχανικών Μηχανολογίας και Κατασκευαστικής / Department of Mechanical and Manufacturing Engineering | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Stylianopoulos, T. [0000-0002-3093-1696] | |
dc.description.totalnumpages | 653-664 | |
dc.gnosis.orcid | 0000-0002-3093-1696 | |